주피터 뉴로사이언시즈(JUNS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.01 (+0.00%), 시가총액 $0.01B, 52주 최저~최고 $0.20 ~ $2.97.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clin
주피터 뉴로사이언시즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
주피터 뉴로사이언시즈의 현재 주가는 $3.01 (+0.00%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
주피터 뉴로사이언시즈의 시가총액은 약 $0.01B입니다.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the